Silo Pharma Announces Closing of $2 Million Public Offering
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) ('Silo' or the 'Company'), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ('Series A-1 Warrants') to purchase up to 3,333,338 shares of common stock and series A-2 warrants ('Series A-2 Warrants') to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire five years thereafter. The Series A-2 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire eighteen months thereafter.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering were approximately $2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general working capital purposes.
A registration statement on Form S-1 (File No. 333-286777) relating to the securities described above has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on May 15, 2025. The offering will be made only by means of a prospectus, which is part of the effective registration statement. A final prospectus relating to the offering has been filed with the SEC on May 16, 2025. Electronic copies of the final prospectus may be obtained for free on the SEC's website located at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected] .
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words 'could', 'believe', 'anticipate', 'intend', 'estimate', 'expect', 'may', 'continue', 'predict', 'potential', and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ('Silo' or 'the Company') to differ materially from the results expressed or implied by such statements, including statements pertaining to the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factor. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
30 minutes ago
- The Hill
Asian shares are mixed as markets shrug at latest China-US trade deal
TOKYO (AP) — Asian shares were trading mixed early Thursday after Wall Street's rally stalled as investors appeared not to react much to the results of the latest round of China-U.S. trade talks. U.S. futures slipped while oil prices rose. Japan's Nikkei 225 lost 0.7% to 38,160.80. Hong Kong's Hang Seng sank 0.7% to 24,206.69, while the Shanghai Composite index edged 0.1% lower to 3,400.30. In South Korea, the Kospi gained 0.4% to 2,919.67, while Australia's S&P/ASX 200 edged 0.1% higher to 8,604.70. On Wednesday, the S&P 500 fell 0.3% to 6,022.24 for its first loss in four days. The Dow Jones Industrial Average was virtually unchanged at 42,865.77 after edging down by 1 point. The Nasdaq composite slipped 0.5% to 3,400.30. All told, the S&P 500 fell 16.57 points to 6,022.24. The Dow Jones Industrial Average slipped 1.10 to 42,865.77, and the Nasdaq composite sank 99.11 to 19,615.88. Several Big Tech stocks led the way lower, and a 1.9% drop for Apple was the heaviest weight on the market. It's been listless this week after unveiling several modest upcoming changes to the software that runs its devices. The action was stronger in the bond market, where Treasury yields eased after a report suggested President Donald Trump's tariffs are not pushing inflation much higher, at least not yet. U.S. consumers had to pay prices for food, gasoline and other costs of living that were 2.4% higher overall in May than a year earlier. That was up from April's 2.3% inflation rate, but it wasn't as bad as the 2.5% that Wall Street was expecting. A fear has been that Trump's wide-ranging tariffs could ignite an acceleration in inflation, just when it had seemed to get nearly all the way back to the Federal Reserve's 2% target from more than 9% three summers ago. It hasn't happened, though economists warn it may take months more to feel the full effect of Trump's tariffs. Trump said Wednesday that China will supply rare-earth minerals and magnets to the United States, while his government will allow Chinese students into U.S. universities in a deal that still needs an agreement by him and by China's leader. Trump also said that 'President XI and I are going to work closely together to open up China to American Trade. This would be a great WIN for both countries!!!' Investors are still hoping for a more sweeping trade deal that would ease tensions between the world's two largest economies. Hopes for such deals between the United States and countries around the world have been one of the main reasons the S&P 500 has charged nearly all the way back to its all-time high after dropping roughly 20% below a couple months ago. Without them, the fear is that Trump's high tariffs could drive the economy into a recession while pushing inflation higher. The S&P 500 is now sitting 2% below its record. Tesla swung between gains and losses before finishing with a rise of 0.1% to continue its shaky run. It's been recovering much of its big losses taken last week after Elon Musk's relationship with Trump imploded, which in turn raised fears about a loss of business for the electric-vehicle company. Musk on Wednesday backed away from some of his earlier comments and said they went 'too far.' In the bond market, the yield on the 10-year Treasury eased to 4.41% from 4.47% late Tuesday. Shorter-term yields, which more closely track expectations for what the Fed will do with overnight interest rates, fell more. Wednesday's better-than-expected reading on inflation raised expectations along Wall Street that the Fed could cut its main interest rate at least twice by the end of the year. In other dealings early Thursday, U.S. benchmark crude oil gained 13 cents to $68.28 per barrel. Brent crude, the international standard, picked up 10 cents to $69.87 per barrel. The U.S. dollar slipped to 144.05 Japanese yen from 144.60 yen. The euro rose to $1.1521 from $1.1487. ___ AP Business Writer Stan Choe contributed.
Yahoo
33 minutes ago
- Yahoo
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
42 minutes ago
- Business Insider
SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst
TD Cowen analyst Shaul Eyal maintained a Buy rating on SailPoint, Inc. (SAIL – Research Report) today. The company's shares closed today at $22.53. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Eyal is a top 25 analyst with an average return of 26.7% and a 69.56% success rate. Eyal covers the Technology sector, focusing on stocks such as Cloudflare, SailPoint, Inc., and Check Point. In addition to TD Cowen, SailPoint, Inc. also received a Buy from Barclays's Saket Kalia in a report issued on June 3. However, today, Mizuho Securities reiterated a Hold rating on SailPoint, Inc. (NASDAQ: SAIL). SAIL market cap is currently $10.94B and has a P/E ratio of -17.86. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SAIL in relation to earlier this year.
